Dossier
Michael Leuchten
Coverage of Michael Leuchten in the Nexus archive.
- STAT+: Pharmalittle: We’re reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more
AstraZeneca's stock fell amid merger talks with Bristol Myers Squibb, which could create a $400 billion drugmaker, while Amgen disclosed a cybersecurity incident involving stolen patient data. Investors questioned the strategic need for the proposed merger, and Bristol Myers Squibb's shares rose in premarket trading.